FBC represented Check-Cap Ltd. in a $7.5 million registered direct offering of units, with each unit consisting of one ordinary share (or ordinary share equivalent) and one Series D warrant to purchase 0.5 ordinary share.
H.C. Wainwright & Co., LLC served as exclusive placement agent for the offering.
Check-Cap, listed on NASDAQ, is advancing the development of C-Scan®, the first and only preparation-free ingestible scanning capsule for the prevention of colorectal cancer (CRC) through the detection of precancerous polyps.
